Current Research: Medical Oncology


Breast


Project

Sponsor

Begin Date

End Date
TAILORx -- Trial Assigning IndividuaLized Options for Treatment (Rx) of ER and/or PR positive breast cancer Eastern Cooperative Oncology Group (ECOG) Dec 2006 Dec 2011
ALTTO -- Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization for HER2/ ErbB2 positive primary breast cancer Sponsor Feb 2009 Dec 2011
C40502—Weekly Paclitaxel Vs Weekly Nanoparticle Albumin bound Nab-Paclitaxel or Ixabepilone combined with Bevacizumab as first-line therapy for metastatic breast cancer Cancer and Leukemia Group B (CALGB) Awaiting IRB Approval April 2011
E5103– Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer Eastern Cooperative Oncology Group (ECOG) Sept 2008 Dec 2009
S0226 -- Anastrozole Vs Anastrozole + Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer Southwest Oncology Group (SWOG) Nov 2005 Jan 2011
B-42 -- Letrozole vs Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an AI, or Tamoxifen Followed by an AI, in Prolonging Disease-Free Survival in HR+ Breast Cancer. National Surgical Adjuvant Breast and Bowel Project (NSABP) Mar 2007 Dec 2011

Gastrointestinal


Project

Sponsor

Begin Date

End Date
C80405 -- Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (FOLFOX) with Bevacizumab, or Cetuximab, or Combination of Bevacizumab and Cetuximab for Metastatic Adenocarcinoma of the Colon or Rectum Cancer and Leukemia Group B (CALGB) Oct 2006 Sept 2011
E5202 -- Oxaliplatin/5-FU/Leucovorin (FOLFOX) vs FOLFOX + Bevacizumab for Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Eastern Cooperative Oncology Group (ECOG) Aug 2007 Aug 2012
E5204 -- Postoperative Oxaliplatin/5-FU/Leucovorin (FOLFOX) vs FOLFOX + Bevacizumab for Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation Eastern Cooperative Oncology Group (ECOG) Aug 2007 Aug 2012
S0502-- Imatinib with or without Bevacizumab for Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST) Southwest Oncology Group
(SWOG)		 Awaiting IRB Approval Jul 2012

Genitourinary


Project

Sponsor

Begin Date

End Date
S0421 -- Docetaxel + Atrasentan Vs Docetaxel + Placebo for Advanced Hormone Refractory Prostate Cancer Southwest Oncology Group
(SWOG)		 Mar 2009 Sept 2012
E2805 -- Adjuvant Sunitinib vs Sorafenib vs Placebo for Resected Renal Cell Carcinoma Eastern Cooperative Oncology Group (ECOG) Mar 2007 Aug 2011

Lung


Project

Sponsor

Begin Date

End Date
E1505 -- Adjuvant Chemotherapy With or Without Bevacizumab for Completely Resected Stage IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) Eastern Cooperative Oncology Group (ECOG) Dec 2007 Jun 2011

Melanoma


Project

Sponsor

Begin Date

End Date
E1697 -- Phase III Randomized Study of Four Weeks High Dose IFN-α2b in Stage T2b No, T3a-b No, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma Eastern Cooperative Oncology Group (ECOG) Dec 1999 Dec 2014

Hematological Malignancies


Project

Sponsor

Begin Date

End Date
E1A06--Melphalan, Prednisone and Thalidomide (MPT) Vs Melphalan, Prednisone and Revlimid (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy Eastern Cooperative Oncology Group (ECOG) Mar 2009 Aug 2010
C100104 -- A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma Cancer and Leukemia Group B (CALGB) Aug 2006 Dec 2009
E2902--Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission of in Remission after Primary Induction Failure or Patients over Age 60 in First Remission Eastern Cooperative Oncology Group (ECOG) Mar 2006 Mar 2010
Revised April 14, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .